AR128985A1 - Forma cristalina de lanifibranor - Google Patents

Forma cristalina de lanifibranor

Info

Publication number
AR128985A1
AR128985A1 ARP230100832A ARP230100832A AR128985A1 AR 128985 A1 AR128985 A1 AR 128985A1 AR P230100832 A ARP230100832 A AR P230100832A AR P230100832 A ARP230100832 A AR P230100832A AR 128985 A1 AR128985 A1 AR 128985A1
Authority
AR
Argentina
Prior art keywords
crystalline form
lanifibranor
diffraction pattern
ray
solution
Prior art date
Application number
ARP230100832A
Other languages
English (en)
Spanish (es)
Inventor
Frdric Bell
Benassa Boubia
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of AR128985A1 publication Critical patent/AR128985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
ARP230100832A 2022-04-05 2023-04-04 Forma cristalina de lanifibranor AR128985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22305456 2022-04-05

Publications (1)

Publication Number Publication Date
AR128985A1 true AR128985A1 (es) 2024-07-03

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100832A AR128985A1 (es) 2022-04-05 2023-04-04 Forma cristalina de lanifibranor

Country Status (14)

Country Link
US (1) US20250243192A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504725A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511847A (cg-RX-API-DMAC7.html)
KR (1) KR20250002337A (cg-RX-API-DMAC7.html)
CN (1) CN119301120A (cg-RX-API-DMAC7.html)
AR (1) AR128985A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023250118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247273A1 (cg-RX-API-DMAC7.html)
IL (1) IL316075A (cg-RX-API-DMAC7.html)
MX (1) MX2024012348A (cg-RX-API-DMAC7.html)
PY (1) PY2324870A (cg-RX-API-DMAC7.html)
TW (1) TW202404966A (cg-RX-API-DMAC7.html)
UY (1) UY40216A (cg-RX-API-DMAC7.html)
WO (1) WO2023194339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022325334A1 (en) * 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof
JP2026501899A (ja) 2023-01-19 2026-01-16 インベンティバ ラニフィブラノール製剤
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AR133887A1 (es) * 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
IL330214A (en) 2023-12-21 2026-08-01 Inventiva Combination therapy for the prevention and/or treatment of liver disease
AU2024409290A1 (en) 2023-12-21 2026-08-06 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
TW202604485A (zh) 2024-05-17 2026-02-01 法商因文帝華公司 患有肝損傷患者肝疾病之治療
WO2026115290A1 (en) 2024-11-28 2026-06-04 Inventiva Non-invasive monitoring of nash treatment with lanifibranor
WO2026125286A1 (en) 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
US20240246949A1 (en) 2021-06-10 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
AU2022325334A1 (en) 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
MX2024012348A (es) 2024-11-08
JP2025511847A (ja) 2025-04-16
EP4504725A1 (en) 2025-02-12
WO2023194339A1 (en) 2023-10-12
TW202404966A (zh) 2024-02-01
UY40216A (es) 2023-10-31
CA3247273A1 (en) 2023-10-12
IL316075A (en) 2024-12-01
PY2324870A (es) 2023-10-27
CN119301120A (zh) 2025-01-10
US20250243192A1 (en) 2025-07-31
KR20250002337A (ko) 2025-01-07
AU2023250118A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
AR124911A1 (es) Sólidos cristalinos del inhibidor mek n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y usos de los mismos
CO2021016594A2 (es) Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
UY29277A1 (es) Derivados de benzamidas (4(4-(1-isopropil-2-metil-1h-imidazol-5-il)-pirimidin-2-il)amino)sustitudas, composiciones que los contienen, procedimiento de preparación y aplicaciones
CY1122611T1 (el) Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης
AR052948A1 (es) DERIVADOS DE ACETILENIL-PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES DEL SNC
PE20240114A1 (es) Inhibidor de integrina y usos de este
Rojo et al. The synthesis and characterisation of strontium and calcium folates with potential osteogenic activity
PE20252755A1 (es) Formas cristalinas de un inhibidor de ras
HN2001000110A (es) 5-cloro -3-(metansulfonilfelino)-6-metil-[2.3] bipiridinilo en forma cristalina pura y proceso para la sintesis
JPH02503318A (ja) 化合物
KR20200103031A (ko) 신규한 mtor 저해제 화합물
AU2013301156A1 (en) Process for the preparation of pemetrexed and lysin salt thereof
PE20251400A1 (es) Derivados de co-cristales de 4-[4-[3-cloro-4-[1- (2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con acido galico y amida nicotinica
Srivastava et al. 4-(Ethoxycarbonyl) phenyl-1-amino-oxobutanoic acid–chitosan complex as a new matrix for silver nanocomposite film: Preparation, characterization and antibacterial activity
CO6270318A2 (es) Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465
Xie et al. Anti-AIDS (acquired immune deficiency syndrome) agents. 17. New brominated hexahydroxybiphenyl derivatives as potent anti-HIV agents
PE20231071A1 (es) Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1- il)fenil]-6-oxo-1,6-dihidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15- tetraazatriciclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona
Ouédraogo et al. 2-Oxo-2H-chromen-7-yl 4-tert-butylbenzoate
Adamovich et al. Biologically active protic (2-hydroxyethyl) ammonium ionic liquids. Liquid aspirin
ES2527354T3 (es) Anhidrato de 8-cloro-3-pentil-3,7-dihidro-1H-purina-2,6-diona 2-amino-2-(hidroximetil)-1,3-propanodiol para el tratamiento de enfermedades
AR064107A1 (es) Polimorfos de motilida, un procedimiento para su preparacion y una formulacion farmaceutica
PE20241624A1 (es) Sal derivada de triazolona como inhibidor de elastasa de neutrofilos
AR083256A1 (es) Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico
AR131692A1 (es) Formas cristalinas o sales de un compuesto deuterado